Kura Oncology
KURA
119 hedge funds and large institutions have $395M invested in Kura Oncology in 2020 Q1 according to their latest regulatory filings, with 13 funds opening new positions, 47 increasing their positions, 41 reducing their positions, and 19 closing their positions.
15% more repeat investments, than reductions
Existing positions increased: 47 | Existing positions reduced: 41
1.52% more ownership
Funds ownership: 86.16% → 87.68% (+1.5%)
6% less funds holding
Funds holding: 127 → 119 (-8)
20% less funds holding in top 10
Funds holding in top 10: 5 → 4 (-1)
26% less capital invested
Capital invested by funds: $537M → $395M (-$142M)
32% less first-time investments, than exits
New positions opened: 13 | Existing positions closed: 19
76% less call options, than puts
Call options by funds: $35K | Put options by funds: $147K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
IC
Ikarian Capital
Dallas,
Texas
|
+$8.7M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$6.3M |
| 3 |
Adage Capital Partners
Boston,
Massachusetts
|
+$5.72M |
| 4 |
BI
BVF Inc
San Francisco,
California
|
+$5M |
| 5 |
PM
Prosight Management
Dallas,
Texas
|
+$4.74M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EC
EcoR1 Capital
San Francisco,
California
|
-$8.36M |
| 2 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$7.72M |
| 3 |
Goldman Sachs
New York
|
-$6.38M |
| 4 |
ORI
Oak Ridge Investments
Chicago,
Illinois
|
-$2.88M |
| 5 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$2.29M |
KURA Hedge Fund Activity: Q1 2020 in Review
119 of the 4,547 institutional investors tracked by Wall St. Rank reported a position in Kura Oncology (KURA) for Q1 2020, worth a combined $395M — down 26% from $537M a quarter earlier.
Sellers outnumbered buyers: 19 funds closed out of KURA and 13 opened new positions — a net loss of 6 holders — while 41 trimmed existing stakes and 47 added.
The largest buyer was Ikarian Capital, opening a new position worth an estimated $8.7M. The largest seller was EcoR1 Capital, cutting an estimated $8.36M.
- 119 institutional investors held Kura Oncology (KURA) as of Q1 2020, down from 127 in Q4 2019.
- Funds reported $395M of Kura Oncology stock for Q1 2020, down 26% quarter-over-quarter.
- 13 funds opened new Kura Oncology positions in Q1 2020 and 19 closed out, a net change of -6 holders.
- The largest Kura Oncology buyer in Q1 2020 was Ikarian Capital, an estimated $8.7M added.
- The largest Kura Oncology seller in Q1 2020 was EcoR1 Capital, an estimated $8.36M sold.
Based on aggregated 13F filings for Q1 2020.